ESTRO meets Asia 2024 - Abstract Book

S103

Interdisciplinary – CNS

ESTRO meets Asia 2024

diameter and presence of chemotherapy after SRS/ SRT have significant differences (p=0.025/ 0.001). The 12 months intracranial recurrence rate was 58.0% (95%CI: 47.7-68.3%). On univariate analysis, primary lesions, number of lesions, presence of chemotherapy before or after SRS/ SRT were significant prognostic factors (p=0.030/ 0.048/ 0.022/ 0.028). On multivariate analysis, presence of chemotherapy before SRS/ SRT have only significant differences (p=0.043). For acute adverse events, there were two cases of Grade1 headache and one case each of Grade2 headache and alopecia. Brain necrosis was seen in 12 lesions. All cases were asymptomatic. Necrosis rate on 12-month was 9% (95%CI: 6.1-11.9%). Maximum tumor diameter and multi-fraction were significant factor of necrosis (p=0.005 and 0.049), but V12Gy was not (p=0.23).

Conclusion:

The mSRS/ SRT system is regarded as a safe and effective treatment modality for multiple brain metastases.

Keywords: brain metases, radiotherapy, single isocenter

References:

Strahlenther Onkol 2021 197:601-613

Adv Radiat Oncol. 2021;6: 100760

Adv Radiat Oncol. 2020; 5(1):70-76

119

Digital Poster

Treatment Outcomes of Craniopharyngioma in Ramathibodi Hospital Thawanrat Pandaeng 1 , Putipun Puataweepong 1 , Padcha Tunlayadechanont 2 , Usanarat Anurathapan 3 , Rasin Worawongsakul 1 1 Division of Radiation Oncology, Department of Diagnostic and Therapeutic Radiology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 2 Division of Diagnostic Radiology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3 Division of Hematology and Oncology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Purpose/Objective:

To evaluate treatment outcomes of craniopharyngioma in Ramathibodi Hospital.

Material/Methods:

A retrospective review of craniopharyngioma patients treated with multimodality treatment between 1990 and 2020 was conducted at Ramathibodi Hospital. The inclusion criteria encompassed all craniopharyngioma patients, while exclusion criteria applied to those diagnosed with other primary brain malignancies (either before or at the time of craniopharyngioma detection) and those who had received previous cranial irradiation. The primary